Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Senzime AB ( (SE:SEZI) ) has shared an announcement.
Senzime AB announced that its CEO, Philip Siberg, will present at the Redeye Medtech & Diagnostics Theme Event and the Biostock Summit. These presentations are part of Senzime’s ongoing efforts to engage with investors and highlight its leadership in personalized anesthesia solutions. The participation in these conferences underscores Senzime’s commitment to advancing its market presence and providing stakeholders with insights into its innovative medical technologies.
The most recent analyst rating on (SE:SEZI) stock is a Hold with a SEK6.00 price target. To see the full list of analyst forecasts on Senzime AB stock, see the SE:SEZI Stock Forecast page.
More about Senzime AB
Senzime is a leading medical device company focused on precision-based monitoring systems that enhance perioperative patient safety. Established in 1999 and headquartered in Uppsala, Sweden, the company is known for its TetraGraph® system, which is widely used for neuromuscular transmission monitoring during surgeries. Senzime is publicly traded on the Nasdaq Stockholm Main Market and cross-traded on the US OTCQX Market.
Average Trading Volume: 471,687
Technical Sentiment Signal: Strong Sell
Current Market Cap: SEK849M
For an in-depth examination of SEZI stock, go to TipRanks’ Overview page.